Pancragen
Also known as: KEDW Tetrapeptide, Lys-Glu-Asp-Trp, Pancreas Bioregulator
Key Facts: Pancragen
- Category
- Metabolic
- FDA Status
- Not FDA Approved
- Clinical Status
- Approved in Russia - Clinical use for pancreatic support
- Administration
- Oral capsules, before meals
- Typical Dose
- 1-2 capsules (10-20 mg) daily
- Frequency
- 1-2x daily, before meals
- Duration
- 30-day courses with 3-6 month breaks
Mechanism of Action
Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Its small size (~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA. May also modulate inflammatory responses and support antioxidant defenses.
Research Summary
Research in old rhesus monkeys demonstrated Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. Studies published in Bulletin of Experimental Biology and Medicine (2013, 2015) show effects on pancreatic cell differentiation during aging. Used clinically in Russia for chronic pancreatitis and type 2 diabetes support.
Dosing Information
Typical Dosingⓘ
Community experience
1-2 capsules (10-20 mg) daily
10-20 mg per day
1-2x daily, before meals
Khavinson bioregulator for pancreatic and metabolic support. Studies in aged rhesus monkeys showed improvement in glucose tolerance. Used in Russia for chronic pancreatitis and as adjunct for type 2 diabetes. Should not replace standard diabetes treatment.
Research Dosingⓘ
Scientific studies
Khavinson bioregulator dosing - clinically used in Russia
Doses from Studies
10-20 mg daily oral
Russian Clinical Practice - Chronic pancreatitis and T2D support protocols ↗
10 mg daily (primate studies)
Bull Exp Biol Med 2013 - Pancragen effects on pancreatic differentiation during aging ↗
Duration
30-day courses with 3-6 month breaks
Administration
Oral capsules, before meals
Timing & Administration
Best Time to Take
Morning, before breakfast
1-2 times daily
Food Recommendation
With or without food
Why This Timing?
Pancreatic support peptide taken fasted for optimal absorption. Timing with meals may support glucose metabolism.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●No significant adverse effects reported in studies
- ●Individual intolerance possible
- ●Should not replace diabetes medications
References
Research This Peptide Further
Frequently Asked Questions
What does Pancragen do?
A synthetic tetrapeptide (Lys-Glu-Asp-Trp) bioregulator originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Studied for age-related metabolic disturbances including type 2 diabetes.
How does Pancragen work?
Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Its small size (~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA. May also modulate inflammatory responses and support antioxidant defenses.
Is Pancragen FDA approved?
No, Pancragen is not currently FDA approved. Current status: Approved in Russia - Clinical use for pancreatic support
What are the side effects of Pancragen?
Reported side effects include: Generally well-tolerated, No significant adverse effects reported in studies, Individual intolerance possible, Should not replace diabetes medications. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Pancragen?
Community-reported common dose: 1-2 capsules (10-20 mg) daily (1-2x daily, before meals). Range: 10-20 mg per day. Administration: Oral capsules, before meals. Community-reported doses. Not FDA approved. Not a substitute for diabetes medication. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Pancragen or used in similar applications.
SLU-PP-332
PreclinicalA synthetic small molecule developed at Saint Louis University that activates estrogen-related receptors (ERRs), mimicking the metabolic effects of aerobic exercise. Technically not a peptide but a small organic molecule (MW 290.32), widely discussed in the peptide community as an "exercise mimetic" that boosts fat oxidation, endurance, and mitochondrial function without stimulant effects.
MetabolicBPC-157
PreclinicalA synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
HealingTB-500
PreclinicalA synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.
HealingSemaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Weight LossIpamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Growth HormoneWant updates on Pancragen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.